Implicit and explicit dosimetry in photodynamic therapy: a New paradigm

Dosimetry for photodynamic therapy (PDT) is becoming increasingly complex as more factors are identified which may influence the effectiveness of a given treatment. The simple prescription of a PDT treatment in terms of the administered photosensitizer dose, the incident light and the drug-light time interval does not account for patient-to-patient variability in either the photosensitizer uptake, tissue optical properties or tissue oxygenation, nor for the interdependence of the photosensitizer-light-tissue factors. This interdependence is examined and the implications for developing adequate dosimetry for PDT are considered. The traditional dosimetric approach, measuring each dose factor independently, and termed here ‘explicit dosimetry’, may be contrasted with the recent trend to use photosensitizer photobleaching as an index of the effective delivered dose, termed here ‘implicit dosimetry’. The advantages and limitations of each approach are discussed, and the need to understand the degree to which the photobleaching mechanism is linked, or ‘coupled’, to the photosensitizing mechanism is analysed. Finally, the influence of the tissue-response endpoints on the optimal dosimetry methods is considered.

[1]  B. Wilson,et al.  IN VIVO and POST MORTEM MEASUREMENTS OF THE ATTENUATION SPECTRA OF LIGHT IN MAMMALIAN TISSUES , 1985, Photochemistry and photobiology.

[2]  J Moan,et al.  Effect of bleaching of porphyrin sensitizers during photodynamic therapy. , 1986, Cancer letters.

[3]  B. Henderson,et al.  DRUG and LIGHT DOSE DEPENDENCE OF PHOTODYNAMIC THERAPY: A STUDY OF TUMOR and NORMAL TISSUE RESPONSE , 1987, Photochemistry and photobiology.

[4]  J Moan,et al.  Photoproducts formed from photofrin II in cells. , 1988, Journal of photochemistry and photobiology. B, Biology.

[5]  J. Moore,et al.  In vivo magnetic resonance imaging of the effects of photodynamic therapy. , 1989, British Journal of Cancer.

[6]  W. Potter,et al.  PDT Dosimetry And Response , 1989 .

[7]  J. Moan,et al.  On the diffusion length of singlet oxygen in cells and tissues , 1990 .

[8]  M S Patterson,et al.  In vivo TESTS OF THE CONCEPT OF PHOTODYNAMIC THRESHOLD DOSE IN NORMAL RAT LIVER PHOTOSENSITIZED BY ALUMINUM CHLOROSULPHONATED PHTHALOCYANINE , 1990, Photochemistry and photobiology.

[9]  M S Patterson,et al.  Experimental tests of the feasibility of singlet oxygen luminescence monitoring in vivo during photodynamic therapy. , 1990, Journal of photochemistry and photobiology. B, Biology.

[10]  A. Welch,et al.  A review of the optical properties of biological tissues , 1990 .

[11]  T. Foster,et al.  Oxygen consumption and diffusion effects in photodynamic therapy. , 1991, Radiation research.

[12]  P Vaupel,et al.  Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. , 1991, Cancer research.

[13]  OPTICAL AND PHOTOBIOLOGICAL DOSIMETRY FOR PHOTODYNAMIC THERAPY OF SOLID TUMORS , 1992 .

[14]  T. Foster,et al.  Dosimetry in photodynamic therapy: oxygen and the critical importance of capillary density. , 1992, Radiation research.

[15]  T L Phillips,et al.  Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. , 1993, Radiation research.

[16]  Studies on pharmacokinetics of sulfonated aluminum phthalocyanine in a transplantable mouse tumor by in vivo fluorescence. , 1993, Journal of photochemistry and photobiology. B, Biology.

[17]  Steven L. Jacques,et al.  How photobleaching affects dosimetry and fluorescence monitoring of PDT in turbid media , 1993, Photonics West - Lasers and Applications in Science and Engineering.

[18]  M G Nichols,et al.  Fluence rate effects in photodynamic therapy of multicell tumor spheroids. , 1993, Cancer research.

[19]  H. Sterenborg,et al.  Quantification of the hematoporphyrin derivative by fluorescence measurementusing dual-wavelength excitation anddual-wavelength detection. , 1993, Applied optics.

[20]  T. Dougherty Photodynamic therapy. , 1993, Photochemistry and photobiology.

[21]  H. Oppelaar,et al.  Changes in perfusion of mouse tumours after photodynamic therapy , 1994, International journal of cancer.

[22]  J. Devoisselle,et al.  In vivo pH MEASUREMENT AND IMAGING OF TUMOR TISSUE USING A pH‐SENSITIVE FLUORESCENT PROBE (5,6–CARBOXYFLUORESCEIN): INSTRUMENTAL AND EXPERIMENTAL STUDIES , 1994, Photochemistry and photobiology.

[23]  W. Mcgimpsey,et al.  AN EFFICIENT OXYGEN INDEPENDENT TWO‐PHOTON PHOTOSENSITIZATION MECHANISM , 1994, Photochemistry and photobiology.

[24]  Brian C. Wilson,et al.  Theoretical study of the influence of sensitizer photobleaching on depth of necrosis in photodynamic therapy , 1994, Photonics West - Lasers and Applications in Science and Engineering.

[25]  W. Star,et al.  In vivo fluorescence kinetics and photodynamic therapy using 5-aminolaevulinic acid-induced porphyrin: increased damage after multiple irradiations. , 1994, British Journal of Cancer.

[26]  Kevin M. Smith,et al.  EVALUATION OF NEW BENZOPORPHYRIN DERIVATIVES WITH ENHANCED PDT EFFICACY* , 1995, Photochemistry and photobiology.

[27]  Hubert van den Bergh,et al.  Clinical measurements of tissue optical properties in the esophagus and in the oral cavity , 1995, Other Conferences.

[28]  W. Star In vivo action spectra, absorption and fluorescence excitation spectra of photosensitizers for photodynamic therapy. , 1995, Journal of photochemistry and photobiology. B, Biology.

[29]  Katsuo Aizawa,et al.  Effectiveness of photodynamic therapy with a diode laser using mono-L-aspartyl chlorin e6 for implanted fibrosarcoma in mice , 1995, Other Conferences.

[30]  T. Hasan,et al.  The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPDMA). , 1995, Journal of photochemistry and photobiology. B, Biology.

[31]  Hubert van den Bergh,et al.  Evaluation with mTHPC of early squamous cell carcinomas of the cheek pouch mucosa of Golden Syrian hamsters as a model for clinical PDT of early cancers in the upper aerodigestive tract, the esophag , 1995, Other Conferences.

[32]  Daniel Braichotte,et al.  Clinical pharmacokinetic studies of tetra(meta‐hydroxyphenyl)chlorin in squamous cell carcinoma by fluorescence spectroscopy at 2 wavelengths , 1995, International journal of cancer.

[33]  Stefan Andersson-Engels,et al.  Multi-colour fluorescence imaging in connection with photodynamic therapy of delta-amino levulinic acid (ALA) sensitised skin malignancies , 1995 .

[34]  Steven L. Jacques,et al.  Kinetics of ALA-induced protoporphyrin IX accumulation in the liver, skin, and tumor of a rat model , 1995, Photonics West.

[35]  Brian C. Wilson,et al.  General-purpose instrument for PDT dosimetry , 1995, Other Conferences.

[36]  R. Pottier,et al.  On the role of protoporphyrin IX photoproducts in photodynamic therapy. , 1995, Journal of photochemistry and photobiology. B, Biology.

[37]  Hubert van den Bergh,et al.  In-vivo measurement of fluorescence bleaching of meso-tetra hydroxy phenyl chlorin (mTHPC) in the esophagus and the oral cavity , 1995, European Conference on Biomedical Optics.

[38]  C. Gomer,et al.  Clinical and preclinical photodynamic therapy , 1995, Lasers in surgery and medicine.

[39]  Thomas H. Foster,et al.  Oxygen sensitivity of PDT determined from time-dependent electrode measurements in spheroids , 1995, Photonics West.

[40]  Dominic J. Robinson,et al.  In vivo monitoring of photosensitizer fluorescence during photodynamic therapy , 1995, Other Conferences.

[41]  G. Wagnières,et al.  Clinical pharmacokinetic studies of photofrin by fluorescence spectroscopy in the oral cavity, the esophagus, and the bronchi , 1995, Cancer.

[42]  John Griffiths,et al.  Measurement of the photodynamic dose in an optical phantom , 1995, Other Conferences.

[43]  Stefan Andersson-Engels,et al.  Photodynamic therapy of nonmelanoma skin malignancies with topical delta-amino levulinic acid: diagnostic measurements , 1994, Other Conferences.

[44]  J. J. Schuitmaker,et al.  Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C. , 1995, British Journal of Cancer.

[45]  Claire Davies,et al.  Threshold effects of PDT in the normal rat colon with ALA photosensitization , 1994, Other Conferences.

[46]  P. Monnier,et al.  Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy , 1996, Lasers in surgery and medicine.

[47]  R. Cubeddu,et al.  In vivo absorption spectrum of disulphonated aluminium phthalocyanine in a murine tumour model. , 1996, Journal of photochemistry and photobiology. B, Biology.

[48]  T. Dougherty,et al.  A brief history of clinical photodynamic therapy development at Roswell Park Cancer Institute. , 1996, Journal of clinical laser medicine & surgery.

[49]  N.T. Songhvi,et al.  New developments in therapeutic ultrasound , 1996 .

[50]  S. Bagdonas,et al.  Spectroscopic studies of photobleaching and photoproduct formation of porphyrins used in tumour therapy. , 1996, Journal of photochemistry and photobiology. B, Biology.

[51]  S M Evans,et al.  Noninvasive imaging of the distribution in oxygen in tissue in vivo using near-infrared phosphors. , 1996, Biophysical journal.

[52]  V. Fingar,et al.  Vascular effects of photodynamic therapy. , 1996, Journal of clinical laser medicine & surgery.

[53]  B. C. Wilson,et al.  The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy. , 1996, British Journal of Cancer.

[54]  L. Bezdetnaya,et al.  Spectroscopic and Biological Testing of Photobleaching of Porphyrins in Solutions * , 1996, Photochemistry and photobiology.

[55]  H J Sterenborg,et al.  Photodynamic therapy with pulsed light sources: a theoretical analysis , 1996, Physics in medicine and biology.

[56]  M. Chopp,et al.  Damage Threshold of Normal Rat Brain in Photodynamic Therapy , 1996, Photochemistry and photobiology.

[57]  L. Grossweiner,et al.  Effects of Photofrin on in vivo skin reflectivity. , 1996, Journal of photochemistry and photobiology. B, Biology.

[58]  M S Patterson,et al.  Absorbed photodynamic dose from pulsed versus continuous wave light examined with tissue-simulating dosimeters. , 1997, Applied optics.

[59]  M G Nichols,et al.  The Mechanism of Photofrin Photobleaching and Its Consequences for Photodynamic Dosimetry , 1997, Photochemistry and photobiology.

[60]  Lothar Lilge,et al.  Photodynamic-therapy-induced alterations of the blood-brain barrier transfer constant of a tracer molecule in normal brain , 1997, Photonics West - Biomedical Optics.

[61]  B. Wilson,et al.  Changes in in vivo optical properties and light distributions in normal canine prostate during photodynamic therapy. , 1997, Radiation research.

[62]  Ting-Yim Lee,et al.  In vivo CT measurement of blood-brain transfer constant of iopamidol in human brain tumors , 1992, Journal of Neuro-Oncology.

[63]  Brian C. Wilson,et al.  Effect of photosensitizer concentration in tissue on the penetration depth of photoactivating light , 1986, Lasers in Medical Science.